| Literature DB >> 30200229 |
Chayanard Phukhamsakda1, Allan Patrick G Macabeo2,3, Kamila Tomoko Yuyama4, Kevin David Hyde5, Marc Stadler6.
Abstract
Roussoella species are well recorded from both monocotyledons and dicotyledons. As part of a research program to discover biologically active compounds from plant-associated Dothideomycetes in Thailand, the strain Roussoella sp. (MFLUCC 17-2059), which represents an undescribed species, was isolated from Clematis subumbellata Kurz, fermented in yeast-malt medium and explored for its secondary metabolite production. Bioassay-guided fractionation of the crude extract yielded the new abscisic acid derivative, roussoellenic acid (1), along with pestabacillin B (2), a related congener, and the cyclodipeptide, cyclo(S-Pro-S-Ile) (3). The structure of 1 was determined by 2D NMR spectroscopy and HR-ESIMS data analysis. Compounds 1 and 2 showed inhibitory activity on biofilm formation by Staphylococcus aureus. The biofilm formation of S. aureus was reduced to 34% at 16 µg/mL by roussoellenic acid (1), while pestabacillin B (2) only showed 36% inhibition at 256 µg/mL. In addition, compound 1 also had weak cytotoxic effects on L929 murine fibroblasts and human KB3-1 cancer cells.Entities:
Keywords: Anti-biofilm; Ascomycota; Pleosporales; structure elucidation
Mesh:
Substances:
Year: 2018 PMID: 30200229 PMCID: PMC6225182 DOI: 10.3390/molecules23092190
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Abscisic acid derivatives and cyclodipeptide from Roussoella sp. MFLUCC 17-2059.
NMR spectroscopic data (MeOH-d4, 700 MHz) for roussoellenic acid (1).
| Position | δH 1 | δC 1 | HMBC 2 |
|---|---|---|---|
| 1 | - | 169.8 | - |
| 2 | 5.62, s | 117.2 | 1, 3, 4, 6 |
| 3 | - | 162.2 | - |
| 4a | 2.82 (ddd, 11.5, 10.5, 4.9) | 35.1 | 1, 2, 3, 6, 1′ |
| 4b | 2.48 (ddd, 11.5, 10.5, 4.9) | ||
| 5a | 1.61 3 | 30.7 | 3, 1′, 2′, 6′ |
| 5b | 1.48 3 | ||
| 6 | 1.90, s | 25.5 | 2, 3, 4, 6 |
| 1′ | 1.50 3 | 50.9 | 4, 2′, 5′, 6′, 7′, 8′, 9′ |
| 2′ | - | 137.7 | - |
| 3′ | 5.31, brs | 121.3 | 1′, 2′, 4′, 7′ |
| 4′ | 1.97 3 | 24.1 | 2′, 3′, 5′ |
| 5a′ | 1.48 3 | 32.8 | 1′, 2′, 5′, 8′, 9′ |
| 5b′ | 1.14 (dd, 7.1, 6.0) | ||
| 6′ | - | 33.7 | - |
| 7′ | 1.72, (d, 1.5) | 23.8 | 1′, 2′, 3′ |
| 8′ | 1.00, s | 28.2 | 1′, 5′, 6′, 9′ |
| 9′ | 0.89, s | 28.1 | 1′, 5′, 6′ 8′ |
1 δ values were established from HSQC-DEPT, COSY and HMBC experiments. 2 HMBC correlations, optimized for 10 Hz, are from the proton(s) stated to the indicated carbon(s). 3 Multiplicity not reported due to overlap of signals.
Figure 2COSY and key HMBC correlations in 1.
Scheme 1Putative biogenetic pathway of 1 and 2.
Antimicrobial and cytotoxic activities of compounds 1 and 2.
| Strain | Compound 1 | Compound 2 | Positive Control (µg/mL) | |
|---|---|---|---|---|
| Bacteria | MIC (µg/mL) | |||
| 66.7 | - | 4.1 | Oxytetracyclin | |
| - | - | 0.4 | Oxytetracyclin | |
| - | - | 3.3 | Oxytetracyclin | |
| 66.7 | - | 0.2 | Oxytetracyclin | |
| - | - | 3.3 | Kanamycin | |
| - | - | 1.7 | Gentamycin | |
| 66.7 | - | 3.3 | Oxytetracyclin | |
| Fungi | ||||
| - | - | 66.7 | Nystatin | |
| 66.7 | - | 33.3 | Nystatin | |
| - | - | 33.3 | Nystatin | |
| - | - | 33.3 | Nystatin | |
| - | - | 33.3 | Nystatin | |
| Cell lines | Cytotoxicity IC50 (µg/mL) | |||
| KB 3.1 HeLa | 14 | - | 5 × 10−4 | epothilone B |
| L929 | 27 | - | 1.1 × 10−3 | epothilone B |
(-) no activity; Starting concentration for antimicrobial assay and cytotoxicity assay were 66.7 and 300 µg/mL, respectively.
Biofilm inhibitory activity of compounds 1 and 2.
| Test Organisms | Compound 1 | Compound 2 | Tetracycline |
|---|---|---|---|
| Biofilm Inhibition % | Biofilm Inhibition % | Biofilm Inhibition % | |
| 98% (256 µg/mL) | 36% (256 µg/mL) | 88% (100 µg/mL) | |
| 83% (128 µg/mL) | 23% (128 µg/mL) | ||
| 73% (64 µg/mL) | - | ||
| 61% (32 µg/mL) | - | ||
| 34% (16 µg/mL) | - |
(-) no activity.